EZH2 Inhibition Reshapes 3D Chromatin Architecture to Induce Immunogenic Phenotype in Small Cell Lung Cancer

Key Points

• Findings show that EZH2 inhibition alters chromatin looping, impacting Class I MHC expression.
• EZH2 inhibition positively influences the immunogenic phenotype, which may enhance treatment effects.
• The approach involves assessing changes in 3D genome structure related to chromatin architecture.
• Clinical implications indicate potential improvements in immunotherapy strategies for small cell lung cancer.